Trial · NCT04823442
Activation of Brown Adipose Tissue Metabolism Using Mirabegron
NCT04823442, Not applicable, Completed, Université de Sherbrooke
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Activation of Brown Adipose Tissue Metabolism Using Mirabegron. Trials, record NCT04823442. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04823442
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Activation of Brown Adipose Tissue Metabolism Using Mirabegron
- NCT number
- NCT04823442
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 9 participants, actual
- Lead sponsor
- Université de Sherbrooke
- Conditions
- Type 2 Diabetes
- Interventions
- Mirabegron, Bisoprolol Fumarate
- First posted
- 2021-03-30
- Last updated
- 2024-12-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in activation of Brown Adipose Tissue (BAT) (oxidative metabolism and blood flow) | 30 minutes before and 210 minutes after drug administration | Measured with 11C-acetate using dynamic PET/CT acquisition. |
| Primary | BAT glucose uptake | 240 minutes after drug administration | Assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning |
| Secondary | Whole-body glucose partitioning | 300 minutes after drug administration | Assessed using i.v. injection of 18FDG with static PET/CT scanning |
| Secondary | Whole-body lipolysis | 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state). | Systemic appearance rate of glycerol and fatty acid determined by perfusion of \[1,1,2,3,3-2H\]-glycerol, \[U-13C\]-palmitate tracers. and concentration of total NEFA, triglycerides, palmitate, oleate, linoleate, glycerol. |
| Secondary | Hepatic Glucose production | 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state). | Systemic appearance rate of glucose determined by perfusion of \[6,6 D2\]-glucose |
| Secondary | Substrate utilisation | 150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state). | VO2 and VCO2 will be measured by indirect calorimetry to calculate carbohydrate and fatty acid oxidation rates. |
| Secondary | BAT lipolysis | baseline and 300 minutes after drug administration | Estimated by quantifying changes in tissue radiodensity with CT. |
| Secondary | Changes in pancreatic and gut hormones | 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state). | measured with ELISA and Milliplex. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04823442
GET https://conductscience.org/api/trials/v1/NCT04823442/registered